Pharma Pulse: UPS's Cold Chain Buildout and AbbVie's $10.9B Immunology Bet

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast bringing you the latest insights shaping patient access, regulatory policy, and healthcare innovation. I'm your host, and let's get into today's headlines.

First up, a major cold-chain infrastructure investment signals just how much pressure is building on pharmaceutical logistics networks.

UPS announced a $48 million buildout of 27 temperature-controlled freight cross-dock facilities across the Americas, Europe, and Asia.

The sites are designed to maintain validated temperature ranges at modal transfer points, the intervals between air and ground transport where excursion risk is highest, and all 27 carry IATA CEIV Pharma certification. The investment comes as novel drug approvals have nearly doubled over the past two decades, biologics demand is projected to grow at more than 8% annually through 2033, and cold-chain failures already cost the industry an estimated $35 billion a year, according to the WHO. For manufacturers of cell and gene therapies, where a failed shipment is not a recoverable event, the case for consolidated, single-custody cold-chain infrastructure is becoming difficult to argue against.

Next, one of the largest M&A moves of the year.

AbbVie announced a deal to acquire Apogee Therapeutics for approximately $10.9 billion, and is expected to close in the third quarter of 2026 pending shareholder approval. The acquisition adds Apogee's full pipeline to AbbVie's immunology portfolio, headlined by zumilokibart, a monoclonal antibody in development, along with two additional clinical-stage inflammatory disease programs.

Turning to trade policy, the USMCA joint review begins July 1st, and pharma's window to prepare is closing.

While automotive and labor provisions are dominating the political discussion, the pharmaceutical industry faces its own supply chain exposure. Switching API suppliers or shifting manufacturing locations requires validation, quality reviews, and regulatory filings. Rohit Tripathi of RELEX Solutions, speaking with Pharmaceutical Commerce, argues that the USMCA review doesn't exist in isolation, either. It sits alongside Strait of Hormuz volatility affecting energy and petrochemical costs, both of which flow directly into the price of active ingredients, solvents, and packaging. His advice: start with a product-level risk map now — identify critical SKUs, single-sourced APIs, and cross-border dependencies — and build scenarios before the negotiations force your hand.

And finally, a market access signal that should be on every commercial team's radar heading into 2027 planning.

PwC's annual medical cost trend report projects pharmacy trend will outpace overall medical trend for the fifth consecutive year, with more than 85% of health plan actuaries surveyed reporting that pharmacy costs are rising faster than overall medical costs. GLP-1 prescriptions doubled in volume year-over-year, FDA approvals have extended eligible patient populations, and new oral formulations are broadening access further. At the same time, employer commitment is fracturing — a Business Group on Health survey found 10% of large employers plan to drop GLP-1 weight-loss coverage in 2027, and only 72% are committed to continuing it. On the oncology side, US cancer drug spending hit $143 billion in 2025 and is projected to climb nearly 60% by 2030, largely through the medical benefit where payer management remains limited. The bottom line: formulary placement, contracting, and direct-access strategy are all in motion simultaneously as 2027 benefit designs take shape.

That's it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access, visit pharmaceuticalcommerce.com. Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.